Abstract
Surgical site infections (SSIs) are commonly caused by Staphylococcus aureus We report that a combination of three monoclonal antibodies (MEDI6389) that neutralize S. aureus alpha-toxin, clumping factor A, and four leukocidins (LukSF, LukED, HlgAB, and HlgCB) plus vancomycin had enhanced efficacy compared with control antibody plus vancomycin in two mouse models of S. aureus SSI. Therefore, monoclonal antibody-based neutralization of multiple S. aureus virulence factors may provide an adjunctive perioperative approach to combat S. aureus SSIs.
Keywords:
ClfA; MRSA; Staphylococcus aureus; alpha-toxin; clumping factor A; hla; leukocidin; surgical.
Copyright © 2019 American Society for Microbiology.
Publication types
-
Research Support, N.I.H., Extramural
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Animals
-
Anti-Bacterial Agents / pharmacology*
-
Antibodies, Monoclonal / pharmacology*
-
Antibodies, Monoclonal, Humanized / pharmacology
-
Bacterial Proteins / immunology
-
Broadly Neutralizing Antibodies / pharmacology
-
Coagulase / immunology
-
Leukocidins / immunology
-
Methicillin-Resistant Staphylococcus aureus / pathogenicity
-
Mice, Inbred C57BL
-
Mice, Inbred Strains
-
Staphylococcal Infections / drug therapy*
-
Staphylococcal Infections / microbiology
-
Surgical Wound Infection / drug therapy*
-
Surgical Wound Infection / microbiology
-
Vancomycin / pharmacology
Substances
-
Anti-Bacterial Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Bacterial Proteins
-
Broadly Neutralizing Antibodies
-
ClfA protein, Staphylococcus aureus
-
Coagulase
-
Leukocidins
-
leukocidin S-component protein, Staphylococcus
-
LukF protein, Staphylococcus aureus
-
suvratoxumab
-
Vancomycin